C1sig
A matrix metalloproteinase-generated neo-epitope fragment of type I collagen, enabling non-invasive assessment of extracellular matrix degradation and mortality risk in cardiovascular disease.
Key features and values
- Quantifies a specific fragment of type I collagen produced by matrix metalloproteinase activity.
- Reflects pathological extracellular matrix remodeling associated with tissue degradation.
- Provides a non-invasive measure of collagen turnover in cardiovascular and fibrotic diseases.
- Supports risk stratification and prognostic assessment in acute and chronic conditions.
- Facilitates monitoring of disease progression and therapeutic response.
- Applicable in research on myocardial infarction, heart failure, and related disorders.
- Complements other biomarkers for a comprehensive evaluation of extracellular matrix dynamics.
Description
The C1sig biomarker assay measures a specific neo-epitope fragment of type I collagen generated through matrix metalloproteinase activity, serving as an indicator of extracellular matrix degradation. This non-invasive assay provides insights into pathological tissue remodeling processes, particularly in cardiovascular diseases such as myocardial infarction and heart failure. By quantifying collagen degradation products, the C1sig assay aids in risk stratification, prognostic evaluation, and monitoring of disease progression and therapeutic efficacy. It serves as a valuable tool in both clinical and research settings for understanding the dynamics of extracellular matrix turnover and its implications in disease pathology.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
